Home Featured Page 272

Featured

Latest

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

ICSS for Assessing the Abuse Potential of Psychedelics

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

PTSF53 – Psychedelics and Creativity, with Laura Dawn

COMPASS Pathways appoints Wayne J Riley MD to its Board of...

Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

9 Women of Color Creating A More Inclusive Psychedelic Movement

Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement

Lobe Sciences Becomes Enterprise Member of NFL Alumni Association

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital...

Nova Mentis Establishes Serotonin Research Centre

1...271272273...306 Page 272 of 306

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and...

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

ICSS for Assessing the Abuse Potential of Psychedelics

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

PTSF53 – Psychedelics and Creativity, with Laura Dawn

COMPASS Pathways appoints Wayne J Riley MD to its Board of...

Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

9 Women of Color Creating A More Inclusive Psychedelic Movement

Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement

Lobe Sciences Becomes Enterprise Member of NFL Alumni Association

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital...

Nova Mentis Establishes Serotonin Research Centre

EDITOR PICKS

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and...

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY